Amg - Model ITRIXII - Sirolimus-Eluting Coronary Stent Implantation System
The ITRIXII Sirolimus-Eluting Coronary Stent Implantation System is the first carbonized stent (Inert Carbon Technology) with a completely biodegradable polymer coating which contains Sirolimus (Rapasorb™) as a highly effective drug for preventing thrombotic and re-stenotic events.
- No stent thrombosis during the entire 2-year follow-up period
- Polymer: Poly (D, L-Lactide-co-Glycolid) Polylactide 50% Polyglycolid 50%
- Drug: Rapamycin
- Coating Degradation: 6 weeks in-vivo
- Drug load: 2.0μg/mm2
- 250 Patients with over two years follow-up
The biodegradable Polymer contains Poly-lactic-co-glycolic acid (PLGA) which will degrade 100% into carbon dioxide and water.
Rapamycin Eluting Coronary Stent Implantation System does not need any other auxiliary polymer like parylene C.
The controlled polymer degradation and release of Rapamycin is designed to terminate simultaneously and is completed within less than three months. This covers exactly the time where the drug is needed at most and is tailored uniquely to various immune response reactions occurring after stent implantation. This is understood as Rapasorb™ - Technology.
